Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNT1 | Q5JUK3 | 20/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | KCNMB1 | Q16558 | 1/20 | 1.00 |
| ▸ | KCNT2 | Q6UVM3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22637578 | 1.00 | KCNT1 (1.00) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL24660636 | 1.00 | KCNT1 (1.00) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL29463490 | 1.00 | KCNT1 (1.00) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL24660192 | 0.93 | KCNT1 (0.86) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL24660722 | 0.93 | KCNT1 (1.00) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL24660543 | 0.93 | KCNT1 (1.00) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL24660574 | 0.93 | KCNT1 (1.00) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL22637968 | 0.92 | KCNT1 (1.00) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL22637970 | 0.92 | KCNT1 (1.00) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL29463530 | 0.92 | KCNT1 (1.00) | KCNT1KCNQ1KCNH2CACNA1CSCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239839-A1 | KCNT1 INHIBITORS COMPRISING AN ISOXAZOLE OR OXADIAZOLE CORE AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| CN-114269340-A | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3962481-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020227101-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | KCNT1 1/4885KCNQ1 4/4885KCNH2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.